RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Esperion Therapeutics Stock

Esperion Therapeutics Employees 2024

Esperion Therapeutics Employees

479

Ticker

ESPR

ISIN

US29664W1053

WKN

A1W1SJ

In 2024, Esperion Therapeutics employed 479 people, a 0% change from the 479 number of employees in the previous year.

Esperion Therapeutics Aktienanalyse

What does Esperion Therapeutics do?

Esperion Therapeutics Inc is a company specialized in researching and developing innovative therapies for the treatment of heart diseases. It was founded in 2008 and is headquartered in Ann Arbor, Michigan. History: The founding of Esperion is closely connected with the history of another pharmaceutical company, Pfizer. In 2003, Pfizer introduced the drug Lipitor, used for treating high cholesterol levels. Lipitor quickly became one of the most successful medications worldwide, generating billions in revenue over the following years. Esperion Therapeutics Inc was founded to develop an alternative to Lipitor that would be better tolerated and potentially more effective. The company relied on the expertise of Dr. Roger Newton, the former research director at Pfizer involved in the development of Lipitor. Business model: Esperion's business model is based on acquiring patents for new compounds and then investigating these compounds in clinical trials. If a compound shows promise, Esperion can apply for approval from the US Food and Drug Administration (FDA) and bring the medication to market. The company has also formed a partnership with Daiichi-Sankyo to market its products in Japan and other Asian countries. Segments: Esperion focuses on developing therapies for the treatment of hyperlipidemia, or high cholesterol levels. This means the company develops medications that lower LDL cholesterol levels and reduce the risk of heart and vascular diseases. One promising compound from Esperion is ETC-1002. This medication is currently being tested in clinical trials and has the potential to be an effective alternative to conventional statins, as it does not have the same undesired effects. Other products: Esperion also has a division called Esperion Diabetes Solutions, which focuses on developing therapies for the treatment of type 2 diabetes. However, this is still in the development stage. Additionally, the company has another compound in clinical development called Bempedoic Acid. This medication acts at the cellular level to inhibit cholesterol synthesis in the body. Conclusion: Esperion Therapeutics is a company specializing in the development of innovative therapies for the treatment of heart diseases. The company focuses on lowering LDL cholesterol levels and reducing the risk of heart and vascular diseases. Esperion's promising product is ETC-1002, which has the potential to be an effective alternative to conventional statins. Through its partnership with Daiichi-Sankyo, the company also has access to Asian markets. Esperion Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Esperion Therapeutics's Employee Base

Esperion Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Esperion Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Esperion Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Esperion Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Esperion Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Esperion Therapeutics stock

How many employees does Esperion Therapeutics have this year?

Esperion Therapeutics has 479 undefined employees this year.

How many employees did Esperion Therapeutics have compared to the previous year?

Compared to the previous year, Esperion Therapeutics had 0% more employees.

What impact did the number of employees have on the company Esperion Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of Esperion Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Esperion Therapeutics?

The number of employees can also have an impact on investors of Esperion Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Esperion Therapeutics affect the company?

An increase in equity of Esperion Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Esperion Therapeutics's equity affect the company?

A reduction in equity of Esperion Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Esperion Therapeutics?

Some factors that can influence the equity of Esperion Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Esperion Therapeutics so important for investors?

The equity of Esperion Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Esperion Therapeutics influence the company?

The number of employees at Esperion Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Esperion Therapeutics evolved in recent years?

In recent years, the number of employees at Esperion Therapeutics has changed by 0.

How many employees does Esperion Therapeutics currently have?

Esperion Therapeutics currently has 479 undefined employees.

Why is the number of employees important for investors of Esperion Therapeutics?

The number of employees is important for investors of Esperion Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Esperion Therapeutics take to change the number of employees?

To change the number of employees, Esperion Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Esperion Therapeutics pay?

Over the past 12 months, Esperion Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Esperion Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Esperion Therapeutics?

The current dividend yield of Esperion Therapeutics is .

When does Esperion Therapeutics pay dividends?

Esperion Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Esperion Therapeutics?

Esperion Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Esperion Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Esperion Therapeutics located?

Esperion Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Esperion Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Esperion Therapeutics from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Esperion Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Esperion Therapeutics in the year 2023?

In the year 2023, Esperion Therapeutics distributed 0 USD as dividends.

In which currency does Esperion Therapeutics pay out the dividend?

The dividends of Esperion Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Esperion Therapeutics

Our stock analysis for Esperion Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Esperion Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.